Marisa Wexler, MS, senior science writer —

Astria Therapeutics is planning the launch of a Phase 3 clinical trial in early 2025 to test different dosing schedules of navenibart, its preventive therapy for hereditary angioedema (HAE). The goal, according to Astria, is to provide flexibility for patients, with different dosing options, should the treatment candidate…

DRI Healthcare Trust, an investment firm, has acquired rights to royalty interest in sebetralstat, an on-demand treatment for hereditary angioedema (HAE) that’s being considered for approval in several countries, including the U.S. For Kalvista Pharmaceuticals, the therapy’s developer, the deal could be worth more than $175 million,…

Most people with hereditary angioedema (HAE) who received treatment with a 50 mg dose of the gene-editing therapy NTLA-2002 in a Phase 2 clinical trial were free from swelling attacks over nearly four months, according to a new study. Compared with a placebo, the 50 mg dose led…

The case of an elderly man who developed acquired angioedema associated with an underlying blood disorder called monoclonal gammopathy was described in a new report, with the researchers noting the condition is “very rare but serious.” The man’s angioedema was controlled only after the underlying monoclonal gammopathy was successfully…

An algorithm that takes into account factors such as the frequency and location of swelling attacks may help distinguish chronic histaminergic angioedema (CHA), which is a form of angioedema, from chronic spontaneous urticaria (CSU), a disorder with similar symptoms. That’s according to a study, “Predictive…

Regulatory authorities in Japan, the U.S., and the European Union have aligned on plans for a Phase 3 clinical trial to test the oral medication deucrictibant as a prophylactic (preventive) treatment to reduce the risk of swelling attacks in people with hereditary angioedema (HAE). With alignment from the U.S.

Authorities in the European Union (EU) have agreed to review Kalvista Pharmaceuticals’ application requesting the approval of oral sebetralstat as an on-demand treatment for swelling attacks in people with hereditary angioedema (HAE). The company’s marketing authorization application (MAA) now will be reviewed by a committee of…

Astria Therapeutics is teaming up with Ypsomed, a Swiss-based company, to develop an autoinjector for its experimental treatment STAR-0215 for hereditary angioedema (HAE). “With STAR-0215’s profile, our goal is to develop a therapy that allows patients to choose an approach that works best for their lives with…

A single dose of the gene-editing therapy NTLA-2002 led to significant reductions in the number of swelling attacks among people with hereditary angioedema (HAE) in a Phase 2 clinical trial. NTLA-2002’s developer, Intellia Therapeutics, announced the study met its main goal, demonstrating that the investigative gene therapy…

The oral medication Orladeyo (berotralstat) is now approved in Peru as a prophylactic, or preventive, treatment to reduce the risk of swelling attacks in people with hereditary angioedema (HAE), ages 12 and older. The approval from Peru’s General Directorate of Medicines, Supplies and Drugs comes just months after…